Cytokines are secreted proteins and function as immune-modulating agents. Their secretions are strictly regulated in human body. Excessive production of cytokines may cause autoimmune diseases or cancer, where neutralizing antibodies targeting these cytokines may be potentially therapeutic. GenScript ProBio offers multiply assays to evaluate the biological activity of the cytokine protein and functionalities of cytokine neutralizing antibodies at drug discovery stage.
Case 1: anti-TNFα antibody neutralization assay
Case 2: IL-6 neutralization assay
Interleukin-6 (IL-6) can be both pro- and anti-inflammatory. IL-6 would induce TF-1 cell proliferation via triggering JAK signaling pathway and STAT3 phosphorylation, which offers a good in vitro model for functionality assessment.
Method 1. TF-1 cell proliferation
IL-6 stimulates proliferation of TF-1 cells
Siltuximab neutralizes IL-6 induced proliferation of TF-1 cells
Method 2. Intracellular STAT3 Phosphorylation
IL-6 stimulates STAT3 phosphorylation of TF-1 cells
Siltuximab neutralizes IL-6 triggered STAT3 phosphorylation of TF-1 cells
Case 3: VEGF reporter assay
Vascular endothelial growth factor (VEGF) is a growth factor that stimulates the formation of blood vessels. In cancer, VEGF may cause angiogenesis and promote tumor progression. The VEGF neutralization assay utilizes a VEGFR reporter gene cell line where an interaction between VEGF and VEGFR would activate luciferase reporter gene expression. In the presence of VEGF antibody (Bevacizumab), VEGF-dependent luciferase reporter gene expression will be inhibited.